Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Invivyd Price Performance

IVVD stock opened at $0.88 on Tuesday. The company’s 50 day simple moving average is $1.13 and its 200-day simple moving average is $2.28. The firm has a market capitalization of $105.43 million, a PE ratio of -0.47 and a beta of 0.66. Invivyd has a 12 month low of $0.84 and a 12 month high of $5.20.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after buying an additional 97,496 shares during the period. Marshall Wace LLP lifted its stake in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after buying an additional 474,301 shares during the period. Duquesne Family Office LLC purchased a new position in shares of Invivyd during the second quarter valued at approximately $629,000. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after buying an additional 77,603 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.